Kyle Carver Sells 18,175 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) CFO Kyle Carver sold 18,175 shares of Evommune stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $22.84, for a total transaction of $415,117.00. Following the completion of the sale, the chief financial officer directly owned 59,335 shares of the company’s stock, valued at approximately $1,355,211.40. This trade represents a 23.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Evommune Trading Down 10.6%

EVMN opened at $19.82 on Wednesday. The firm has a fifty day moving average of $24.12. The company has a market capitalization of $713.95 million and a P/E ratio of -2.09. Evommune, Inc. has a 1-year low of $13.89 and a 1-year high of $33.20.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. As a group, analysts forecast that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EVMN has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on shares of Evommune in a research note on Friday, May 1st. They issued a “buy” rating and a $54.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Evommune in a research note on Tuesday, May 26th. Evercore reiterated an “outperform” rating and issued a $55.00 target price on shares of Evommune in a research note on Tuesday, February 10th. Clear Str upgraded shares of Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $49.25.

Institutional Trading of Evommune

A number of institutional investors have recently modified their holdings of EVMN. Capricorn Fund Managers Ltd purchased a new stake in shares of Evommune during the 4th quarter valued at approximately $1,027,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune during the 4th quarter valued at approximately $34,000. Sectoral Asset Management Inc. purchased a new stake in shares of Evommune during the 4th quarter valued at approximately $10,084,000. Geode Capital Management LLC purchased a new stake in shares of Evommune during the 4th quarter valued at approximately $1,881,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of Evommune during the 4th quarter valued at approximately $1,284,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.